Trial Search Results

Blood Pressure Lowering in Acute Stroke Trial (BLAST)

Patients who are suffering from a stroke often present to the hospital with elevated blood pressure. Elevated blood pressure in the setting of stroke increases the risk of brain swelling or bleeding into the brain. Even so, there has been concern about lowering the blood pressure with medications because the newly injured parts of the brain may not get the blood flow they need, thereby worsening the damage from the initial stroke. We hope to demonstrate that the drug valsartan can be used safely and modestly to lower blood pressure in acute stroke patients, without having a detrimental effect on brain blood flow or neurologic status. Novel MRI techniques to measure brain blood flow will be used in conjunction with clinical scales to demonstrate safety.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: Novartis Pharmaceuticals

Stanford Investigator(s):

Intervention(s):

  • Drug: Valsartan

Phase:

N/A

Eligibility


Inclusion Criteria:

   1. Men and non-pregnant women over age 18 who have had an acute ischemic stroke referable
   to the anterior circulation, as diagnosed by one of more of the following: clinical
   judgment, head CT, and/or MR imaging [i.e. a positive diffusion-weighted imaging (DWI)
   abnormality].

   2. Clinical syndrome not likely to represent transient ischemic attack (TIA) or other
   non-stroke etiology

   3. Patient must be neurologically stable at the time of first MRI scan (i.e. stable NIH
   Stroke Scale score).

   4. Initial MRI scan obtainable within 48 hours of symptom onset.

   5. A pre-existing diagnosis of hypertension, either treated or untreated.

   6. Average of two mean arterial blood pressures (separated by at least five minutes) at
   time of enrollment.

Exclusion Criteria:

   1. Patients who have taken an angiotensin-converting enzyme (ACE) inhibitor or
   angiotensin receptor blocker (ARB) within seven (7) days of admission.

   2. Patients who received intravenous or intra-arterial r-TPA for their current symptoms,
   or those who underwent mechanical thrombolysis.

   3. Patients with hemorrhagic strokes, as seen on the initial head CT.

   4. Patients with stroke-like symptoms, but no demonstrable lesion on DWI, or a DWI lesion
   < 2 cm in diameter (greatest dimension).

   5. Patients with high-grade (>70%) internal carotid artery stenosis or occlusion
   ipsilateral to the current stroke.

   6. Patients with high-grade aortic or mitral stenosis.

   7. Patients with a previous adverse reaction to valsartan or other ARBs.

   8. Patients with contraindications for MRI, including pacemakers, claustrophobia, or
   severe obesity.

   9. Patients who are medically unstable for MR imaging, as determined by the treating
   team.

10. Patients with a severe co-existing disease that may interfere with the conduct of the
   study.

11. Patients receiving investigational drug therapies.

12. Informed consent cannot be obtained from the patient or an appropriate surrogate.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305